MIRA Pharmaceuticals (NASDAQ:MIRA) | MIRA Pharmaceuticals Introduces Ketamir-2 as a Promising Alternative for Pain Treatment
MIRA Pharmaceuticals announced that its novel oral ketamine analogue, ketamir-2, showed improved pain relief in preclinical studies compared to gabapentin and pregabalin. This development highlights ketamir-2 as a potential alternative for patients suffering from neuropathic pain, providing effective relief without the risks associated with opioid use. The study demonstrated that ketamir-2 outperformed pregabalin by 112% … Read more